



PATENT  
Docket No. 265.00390101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Boldogh et al.	)	Group Art Unit:	1653
		)		
Serial No.:	10/691,330	)	Examiner:	Chih Min Kam
Confirmation No.:	1384	)		
		)		
Filed:	October 22, 2003	)		

For: USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND  
ANALOGS THEREOF AS INHIBITORS OF APOPTOSIS AND OTHER  
CELLULAR DAMAGE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Per M.P.E.P. § 609, the information cited in the present Supplemental Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested. Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

Since this Supplemental Information Disclosure Statement is submitted after the receipt of an Office Action in the above-identified patent application, please charge Deposit Account No. 13-495 the fee of \$180 under 37 C.F.R. §§1.97(c) and 1.17(p). Please charge any additional fees or credit any overpayment to Deposit Account No. 13-4895.

**Supplemental Information Disclosure Statement**

Page 2 of 2

Applicant: Boldogh et al.

Serial No.: 10/691,330

Filed: October 22, 2003


Title: USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND ANALOGS THEREOF AS INHIBITORS OF APOPTOSIS AND OTHER CELLULAR DAMAGE

---

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

**CERTIFICATE UNDER 37 C.F.R. 1.10:**

The undersigned hereby certifies that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated below and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Name: Sara E. Wigant  
"Express Mail" mailing label number:  
EV 201894274 US  
Date of Deposit: March 20, 2006

Respectfully submitted

By

Muetting, Raasch & Gebhardt, P.A.

P.O. Box 581415


Minneapolis, MN 55458-1415

Phone: (612)305-1220

Facsimile: (612)305-1228

**Customer Number 26813**

March 20, 2006  
Date

By:   
Nancy A. Johnson  
Reg. No. 47,266  
Direct Dial (612)305-4723



<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 265.00390101	<b>Serial No.:</b> 10/691,330
	<b>Applicant(s):</b> Boldogh et al.	<b>Confirmation No.:</b> 1384
	<b>Application Filing Date:</b> 22 October 2003	<b>Group:</b> 1653
	Information Disclosure Statement mailed: March <u>20</u> , 2006	

**U.S. PATENT DOCUMENTS**

Examiner Initial	Copy Enclosed	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		6,939,847	09/06/05	Stanton et al.			

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Copy Enclosed	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
		None						

**OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)**

Examiner Initial	Copy Enclosed	Document Description
	X	Polish Society of Psychiatry Psychogeriatric and Alzheimer's Disease Section, "Treatment of Psychiatric Disorders in Aged Patients," <i>First International Symposium on Colostrinin</i> , ReGen Therapeutics Plc, 1 December 2000, Lodz Poland, Brochure.

<b>EXAMINER</b>	<b>Date Considered</b>
<small>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	